Skip to main content
Top
Published in: AIDS and Behavior 2/2024

21-12-2023 | Human Immunodeficiency Virus | Original Paper

Understanding Oral PrEP Interest, Uptake, Persistence, and Experience of Use Among Heterosexual Men in Johannesburg, South Africa: An Exploratory Pilot Study

Authors: Erica Felker-Kantor, Letitia Rambally Greener, Suzanne Mabaso, Wentzel Kruger, Nina Hasen, Anu Khosla, Shawn Malone

Published in: AIDS and Behavior | Issue 2/2024

Login to get access

Abstract

South Africa’s PrEP programming has primarily focused on men who have sex with men and other key populations through dedicated clinical and outreach services. However, data shows that the pool of men vulnerable to contracting HIV extends beyond this group, including men who have sex only with women and who do not identify as gay. The aim of this pilot study was to assess acceptability of PrEP among this subset of men who are at risk of HIV acquisition in South Africa and to describe the demographic and behavioral characteristics of male PrEP users as well as their experience of PrEP use. We employed a mixed-methods study design consisting of in-depth interviews and quantitative analysis of routine clinic data collected between September 2021 and February 2022 from 10 private health facilities. Men who enrolled in the study and initiated PrEP had low consistent condom use and nearly three quarters reported more than one sexual partner in the past three months. Despite minimal follow-up support, PrEP persistence was relatively high and similar to other populations. 57% of men returned for their 1-month visit, 40% returned for their 4-month visit, and 16% returned for their 7-month visit. The greatest barriers to ongoing use were the need to take a daily pill and low perceived HIV risk. To improve uptake and continuation, programs should increase awareness of PrEP, leverage trusted sources to build credibility, make access more convenient, and accommodate flexible use through event-driven PrEP.
Appendix
Available only for authorised users
Literature
1.
go back to reference Spinner C, Boesecke C, Zink A, Jessen H, Stellbrin HJ, et al. HIV pre-exprosure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016;44:151–8.CrossRefPubMed Spinner C, Boesecke C, Zink A, Jessen H, Stellbrin HJ, et al. HIV pre-exprosure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016;44:151–8.CrossRefPubMed
2.
go back to reference World Helath Organization. Guidance on Pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and Transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. Geneva: World Health Organization; 2012. World Helath Organization. Guidance on Pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and Transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. Geneva: World Health Organization; 2012.
3.
go back to reference Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. Preexposure Chemoprophylaxis for HIV Prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. Preexposure Chemoprophylaxis for HIV Prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
4.
go back to reference World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: WHO; 2014. World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: WHO; 2014.
5.
go back to reference Hannaford A, Lim J, Moll A, Khoza B, Shenoi S. PrEP should be for men only’: young heterosexual men’s views on PrEP in rural South Africa. Glob Public Health. 2020;15(9):1337–48.CrossRefPubMed Hannaford A, Lim J, Moll A, Khoza B, Shenoi S. PrEP should be for men only’: young heterosexual men’s views on PrEP in rural South Africa. Glob Public Health. 2020;15(9):1337–48.CrossRefPubMed
6.
go back to reference Stone J, Mukandavire C, Boily MC, Fraser H, Mishra S, et al. Estimating the contribution of key populations towards HIV transmission in South Africa. J Int AIDS Soc. 2021;24:e252650.CrossRef Stone J, Mukandavire C, Boily MC, Fraser H, Mishra S, et al. Estimating the contribution of key populations towards HIV transmission in South Africa. J Int AIDS Soc. 2021;24:e252650.CrossRef
7.
go back to reference South Africa’s National Strategic Plan for HIV, TB., and STIS. The South African National AIDS Council; 2018. South Africa’s National Strategic Plan for HIV, TB., and STIS. The South African National AIDS Council; 2018.
8.
go back to reference UNAIDS. A snapshot of men and HIV in South Africa. Geneva: UNAIDS; 2017. UNAIDS. A snapshot of men and HIV in South Africa. Geneva: UNAIDS; 2017.
9.
go back to reference Makusha T, van Rooyen H, Cornell M. Reframing the approach to heterosexual men in the HIV epidemic in sub-saharan Africa. J Int AIDS Soc. 2020;23:e25510.CrossRefPubMedPubMedCentral Makusha T, van Rooyen H, Cornell M. Reframing the approach to heterosexual men in the HIV epidemic in sub-saharan Africa. J Int AIDS Soc. 2020;23:e25510.CrossRefPubMedPubMedCentral
11.
go back to reference Berner-Rodereda A, Geldsetzer P, Baringhausen K, Hetterma A, Bäringhausen T, et al. It’s hard for us ment to go to the clinic. We naturally have a fear of hospitals. Men’s risk perceptions, experiences and program preferences for PrEP: a mixed methods study in Eswatini. PLoS ONE. 2020;15(9):e0237427.CrossRef Berner-Rodereda A, Geldsetzer P, Baringhausen K, Hetterma A, Bäringhausen T, et al. It’s hard for us ment to go to the clinic. We naturally have a fear of hospitals. Men’s risk perceptions, experiences and program preferences for PrEP: a mixed methods study in Eswatini. PLoS ONE. 2020;15(9):e0237427.CrossRef
12.
go back to reference Young I, FLowers P, McDaid L. Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland. BMJ Open. 2014;4(11):e005717.CrossRefPubMedPubMedCentral Young I, FLowers P, McDaid L. Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland. BMJ Open. 2014;4(11):e005717.CrossRefPubMedPubMedCentral
13.
go back to reference Stephenson R, Darbes L, Chavanduka T, Essack Z, van Rooyen H. HIV Testing, Knowledge and willingness to Use PrEP among Partnered men who have sex with men in South Africa and Namibia. AIDS Behav. 2021;25:1994–2004.CrossRef Stephenson R, Darbes L, Chavanduka T, Essack Z, van Rooyen H. HIV Testing, Knowledge and willingness to Use PrEP among Partnered men who have sex with men in South Africa and Namibia. AIDS Behav. 2021;25:1994–2004.CrossRef
14.
go back to reference Bell J, Sharma S, Malone S. A study on the drivers of and barriers to PrEP among young men in Mpumalanga and KwaZuluNatal, South Africa. Kigali: ICASA; 2019. Bell J, Sharma S, Malone S. A study on the drivers of and barriers to PrEP among young men in Mpumalanga and KwaZuluNatal, South Africa. Kigali: ICASA; 2019.
15.
go back to reference Reyniers T, Nöstlinger C, Laga M, De Baetselier I, Crucitti T, et al. Choosing between Daily and Event-Driven pre-exposure Prophylaxis: results of a Belgian PreP Demonstation Project. J Acquir Immune Defic Syndr. 2018;79(2):186–94.CrossRefPubMed Reyniers T, Nöstlinger C, Laga M, De Baetselier I, Crucitti T, et al. Choosing between Daily and Event-Driven pre-exposure Prophylaxis: results of a Belgian PreP Demonstation Project. J Acquir Immune Defic Syndr. 2018;79(2):186–94.CrossRefPubMed
16.
go back to reference Olsen T, Lally-Montgomery Z, Kelsberg G, Safranek S. Is event-driven PrEP dosing for HIV effective as daily dosing? J Fam Pract. 2021;70(5):235–55. Olsen T, Lally-Montgomery Z, Kelsberg G, Safranek S. Is event-driven PrEP dosing for HIV effective as daily dosing? J Fam Pract. 2021;70(5):235–55.
17.
go back to reference Van der Elst EM, Mbogua J, Operario D, Mutua G, Huo C et al. Acceptability of HIV Pre-exposure Prophylaxis but challenges in Adherence and Use: qualitative insights from a phase I trial of intermittent and daily PrEP in At-Risk populations in Kenya. AIDS Behav. 2013;17(6). Van der Elst EM, Mbogua J, Operario D, Mutua G, Huo C et al. Acceptability of HIV Pre-exposure Prophylaxis but challenges in Adherence and Use: qualitative insights from a phase I trial of intermittent and daily PrEP in At-Risk populations in Kenya. AIDS Behav. 2013;17(6).
18.
go back to reference Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, et al. Safety and adherence to intermittent Pre-exposure Prohylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS ONE. 2012;7(4):e33103.ADSCrossRefPubMedPubMedCentral Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, et al. Safety and adherence to intermittent Pre-exposure Prohylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS ONE. 2012;7(4):e33103.ADSCrossRefPubMedPubMedCentral
Metadata
Title
Understanding Oral PrEP Interest, Uptake, Persistence, and Experience of Use Among Heterosexual Men in Johannesburg, South Africa: An Exploratory Pilot Study
Authors
Erica Felker-Kantor
Letitia Rambally Greener
Suzanne Mabaso
Wentzel Kruger
Nina Hasen
Anu Khosla
Shawn Malone
Publication date
21-12-2023
Publisher
Springer US
Published in
AIDS and Behavior / Issue 2/2024
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-023-04246-2

Other articles of this Issue 2/2024

AIDS and Behavior 2/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.